Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Japan has approved cancer drug Keytruda's pairing with another drug to treat certain kidney cancer patients.

What This Regulatory Approval Could Mean for Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company's broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors today starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis. “Cardiovascular disease remains the leading cause of

Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Merck (MRK) Keep the Earnings Surprise Streak Alive?

Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Merck's (MRK) Pneumococcal Vaccine sBLA Faces FDA Delay

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck's HPV Vaccine Supply and Support Broader and Equitable Access

Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck's HPV Vaccine Supply and Support Broader and Equitable Access

Bristol-Myers

2 Drugmakers Set for Explosive Revenue This Decade

Merck MRK, -0.42% and privately held Ridgeback Biotherapeutics said Friday they will present data showing that treatment with their COVID-19 antiviral ended infectious illness more rapidly than placebo in a late-stage trial. Data on the treatment, called molnupiravir in the U.S., will be presented at the 2022 European Congress of Clinical Microbiology & Infectious Diseases, the companies said in a joint statement.

Merck and Ridgeback to present data showing COVID antiviral ends infectious illness more quickly than placebo

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ for Use in Infants and Children

Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck & Ridgeback to Present Data Demonstrating LAGEVRIO (molnupiravir) Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

Cisco Systems

Devon Energy

From pharmaceuticals to energy, these are the best cash cow stocks to buy if you're looking to add stability to your portfolio. The post 3 Cash Cow Stocks to Buy for Stable Returns appeared first on InvestorPlace.

3 Cash Cow Stocks to Buy for Stable Returns

Amgen

Caterpillar

Celsius Holdings

Chevron

Enphase Energy

Home Depot

Intrepid Potash

Coca-Cola

Loop Industries

Ouster, Inc

Procter & Gamble

Trillium Therapeutics

Travelers

Walmart

Two sample Breakout Stocks for Week 13 with better than 10% short-term upside potential and a Dow stock pick.

Week 13 MDA Breakout Stocks - April 2022: Short-Term Picks To Give You An Edge

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for KEYTRUDA for Patients With MSI-H or dMMR Tumors in Five Different Types of Cancer

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Positive EU CHMP Opinion for KEYTRUDA Plus Chemo +/- Bev, as Treatment for Persistent, Recurrent or Metastatic Cervical Cancer PD-L1 (CPS ≥1)

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Altria

MRK and MO might not seem like they go together too well, but the actual underlying business is what matters for an income investor.

Merck And Altria: Opposites Providing Regular Growing Income

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.

Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer

Hewlett Packard

Intel

Johnson & Johnson

Mondelez

Tyson Foods

Whirlpool

Investors love dividend stocks because they not only provide dependable income but also give investors a great opportunity for solid total return.

8 Top Analyst ‘Rock Solid' Dividend Stocks to Buy Now for Growth, Dependable Income and Safety

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Review and Meta-Analysis of Real-World Studies Provide Evidence of Effectiveness of PREVYMIS in Preventing CMV Disease in Adults Undergoing AlloHCT

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With MSI H/dMMR Advanced Endometrial Carcinoma

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation

Huntington Ingalls Industries

Jack in the Box

Despite markets enjoying their best week of the year, the S&P 500 Index is still down more than more than 6% for 2022.

3 Undervalued Stocks Outperforming the S&P 500

AbbVie

Moderna

These health care stocks could be worth a look as the stock market moves sideways.

3 Top Health Care Stocks To Watch Right Now

Gilead Sciences

Eli Lilly

Pfizer

Walgreens

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

Fund Managers Pile Into Big Dividend Health Care Stocks: 8 ‘Strong Buy' Winners

Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.

Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%

AstraZeneca

Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Significantly Improved DFS Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA NSCLC Regardless of PD-L1 Expression

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

News for Merck Stock (MRK)